20241031-东吴证券-中国人寿-601628.SH-2024年三季报点评_净资产较快增长_种子计划_加速推进_6页_593kb

Abstract Summary of China Life Insurance Co., Ltd. (601628) 2024 Q3 Performance Report

Key Points:

1. Performance Overview: China Life Insurance (601628) reported Q3 2024 earnings that exceeded expectations, with a 1739% year-on-year growth in attributable net profit. This was driven by stock market rebound, improving investments, and data adjustments under new accounting standards, contributing to a cumulative net profit growth of 1941% compared to the previous year under comparable standards.

2. New Accounting Standards Analysis: Due to the adoption of IFRS17 for insurance and optional non-traceable IFRS9 for investments, the profit figures reflect higher growth. The increase in total and net investment gains was significant, linked to equity market performance.

3. New Business Value (NBV) Growth: NBV saw a 251% year-on-year increase for the period, reflecting strong premium growth and margin improvements. Factors included optimized product and term structures, cost reductions, and effective sales strategies like the "Seed Plan", which is expanding in key cities.

4. Sales Force Development: Total sales personnel reached 6.94 million, indicating a slight decline but steady recovery. Training enhancements and reforms improved efficiency, with individual premium income rising by 17.7%.

5. Profit Forecast and Rating: UBS maintains its "Buy" recommendation, expecting continued profit growth over 2024-2026. Risks include equity market volatility and interest rate trends.

This summary captures the core elements and aligns with the report's focus on performance metrics and outlook, without exceeding the word limit.